Serious Toxicities Associated with Stereotactic Body Radiotherapy (SBRT) and Strategies to Reduce the Risks
In the recent years, there has been a sharp increase of interest in the use of SBRT for the treatment of various primary and metastatic tumors of various organ sites. While promising results have been achieved in terms of tumor control and survival, serious toxicities have also been observed in various organs-at-risk. This session will provide a most up-to-date site by site account of serious complications from SBRT (what can go wrong) and strategies and maneuvers to minimize the risks of those complications (how to prevent them from happening). The data will be updated up to 1-2 weeks before the meeting. All the speakers have more than 10 years of experience in SBRT practice and research at high volume centers and have published extensively in the field of SBRT (peer-reviewed papers and textbooks).
This program is designed to meet the interest of radiation oncologists, physicists, nurses, radiation therapists, dosimetrists, radiation biologists and radiation oncology residents.
- Describe the reported toxicities associated with SBRT for various organ sites and the factors predictive of serious toxicities from SBRT
- Describe potential ways to reduce the risks of serious complications from SBRT
- Determine most commonly used normal tissue constraints for SBRT for various body sites
- Simon Lo, MB, ChB, FACR has compensation/funding from Electra AB.
- Ben Slotman, MD, PhD has compensation/funding from Varian MEdical System, Inc.
- Arjun Sahgal has compensation/funding from Elextra AB and Medtronic.
- Bin Teh, MD has nothing to declare.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.